Rohan  Palekar net worth and biography

Rohan Palekar Biography and Net Worth

CEO of 89bio
Rohan Palekar serves as Chief Executive Officer, Director of the Company. Mr. Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from December 2015 to July 2017, where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar also served as Executive Vice President and Chief Operating Officer of Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr. Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to 2011, where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, in various senior commercial and strategic management roles.

What is Rohan Palekar's net worth?

The estimated net worth of Rohan Palekar is at least $4.07 million as of February 26th, 2024. Mr. Palekar owns 486,889 shares of 89bio stock worth more than $4,070,392 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Palekar may own. Additionally, Mr. Palekar receives an annual salary of $990,520.00 as CEO at 89bio. Learn More about Rohan Palekar's net worth.

How old is Rohan Palekar?

Mr. Palekar is currently 58 years old. There are 3 older executives and no younger executives at 89bio. Learn More on Rohan Palekar's age.

What is Rohan Palekar's salary?

As the CEO of 89bio, Inc., Mr. Palekar earns $990,520.00 per year. Learn More on Rohan Palekar's salary.

How do I contact Rohan Palekar?

The corporate mailing address for Mr. Palekar and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at [email protected]. Learn More on Rohan Palekar's contact information.

Has Rohan Palekar been buying or selling shares of 89bio?

Rohan Palekar has not been actively trading shares of 89bio within the last three months. Most recently, Rohan Palekar sold 4,477 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $10.76, for a transaction totalling $48,172.52. Following the completion of the sale, the chief executive officer now directly owns 486,889 shares of the company's stock, valued at $5,238,925.64. Learn More on Rohan Palekar's trading history.

Who are 89bio's active insiders?

89bio's insider roster includes Gregory Grunberg (Director), Ryan Martins (CFO), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.

Are insiders buying or selling shares of 89bio?

In the last twelve months, 89bio insiders bought shares 1 times. They purchased a total of 1,350,000 shares worth more than $20,722,500.00. In the last twelve months, insiders at the sold shares 5 times. They sold a total of 51,910 shares worth more than $942,909.15. The most recent insider tranaction occured on March, 4th when Director Ra Capital Management, L.P. bought 1,350,000 shares worth more than $20,722,500.00. Insiders at 89bio own 4.4% of the company. Learn More about insider trades at 89bio.

Information on this page was last updated on 3/4/2024.

Rohan Palekar Insider Trading History at 89bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/26/2024Sell4,477$10.76$48,172.52486,889View SEC Filing Icon  
6/5/2023Sell15,000$20.00$300,000.00286,978View SEC Filing Icon  
3/23/2023Sell15,000$16.00$240,000.00269,080View SEC Filing Icon  
1/27/2022Buy5,000$7.50$37,500.00View SEC Filing Icon  
See Full Table

Rohan Palekar Buying and Selling Activity at 89bio

This chart shows Rohan Palekar's buying and selling at 89bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

89bio Company Overview

89bio logo
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $8.36
Low: $8.19
High: $8.45

50 Day Range

MA: $11.03
Low: $8.25
High: $13.77

2 Week Range

Now: $8.36
Low: $6.57
High: $22.93

Volume

168,304 shs

Average Volume

1,215,588 shs

Market Capitalization

$796.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04